Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation

Breast Cancer Research and Treatment

Volumn 55, Issue 2, 1999, Pages 161-167

  Han, Sehwan ^a   Park, Kyeongmee ^a   Kim, Hong Yong ^a   Lee, Myung Soo ^a   Kim, Hong Joo ^a   Kim, Young Duck ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Breast cancer; Cell cycle; Cyclin dependent kinase inhibitor; Differentiation; p27Kip1; Prognosis; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN P27;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0032796973     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006258222233     Document Type: Article

References (27)

1. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14: 3683-3694, 1994
2. Catzavelos GC, Bhattacharia N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1protein: Prognostic implications in primary breast cancer. Nature Med 3: 227-230, 1997
3. Lloyd RV, Jin L, Qian X, Kulig E: Aberrant p27Kip1 expression in endocrine and other tumors. Am J Pathol 150: 401-407, 1997
4. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhihitor p27 in aggressive colorectal carcinomas. Nature Med 3: 231-234, 1997
5. Mori M, Mimori K, Shiraishi T, Tanaka S, Uco H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 3: 593, 1997
6. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nature Med 3: 222-225, 1997
7. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP: p27/Kip1 mutation found in breast cancer. Cancer Res 56: 2400-2404, 1996
8. Ferrando AA, Balbin M, Pendas AM, Vizoso F, Velasco G, Lopez-Otin C: Mutational analysis of the human cyclin-dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Human Genetics 97: 91-94, 1996
9. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Young YL, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55: 2266-2269, 1995
10. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C: p27Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211-1214, 1995
11. Rasmussen UB, Wolf C, Mattei MG, Belloeq JP, Chambon P, Rio MC, Basset P: Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 13q32 and its expression in breast carcinoma. Cancer Res 53: 4096-4101, 1993
12. Yashui W, Kubo Y, Semba S, Yokozaki H, Tahara E: Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88: 625-629, 1997
13. Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG: Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer: Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 65: 22-27, 1997
14. Jordan RCK, Bradley G, Slingerland J: Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 152: 585-590, 1998
15. Kranenburg O, Scharnhorst V, Van de Eb A, Zantema A: Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131: 227-234, 1995
16. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare JM, Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(Kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385, 1997
17. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997
18. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994
19. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744, 1996
20. Toyoshima H, Hunter P: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994
21. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM: Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994
22. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J: G1 control in mammalian cells. J Cell Sci Suppl 18: 69-73, 1994
23. Steeg PS, Abrams JS: Cancer prognostics: Past, present and p27. Reduced expression of the p27 cell cycle inhibitor predicts poor cancer patient survival. Nature Med 3: 152-154, 1997
24. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomota N, Monden T, Rotterdam H, Weinstein B: Localization and expression of p27Kip1 in multistage colorectal carcinogenesis. Cancer Res 58: 114-122, 1998
25. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58: 542-548, 1998
26. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi G, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58: 1730-1735, 1998
27. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudomi T, Takahashi T: p27Kip1 in human lung cancers: Differential changes in small cell and non-small cell carcinomas. Cancer Res 58: 1042-1047, 1998